Reflexive Eye Closure in Response to Cone and Melanopsin Stimulation: A Study of Implicit Measures of Light Sensitivity in Migraine

Author(s):
Eric A Kaiser, MD/PhD\(^1\); Harrison McAdams, PhD\(^2\); Aleksandra Igdalova, BA\(^1\); Edda B Haggerty, BA\(^1\); Brett L Cucchiara, MD\(^1\); David H Brainard, PhD\(^3\); Geoffrey K Aguirre, MD, PhD\(^1\)

Corresponding Author:
Eric A Kaiser
eric.kaiser@pennmedicine.upenn.edu

Neurology® Published Ahead of Print articles have been peer reviewed and accepted for publication. This manuscript will be published in its final form after copyediting, page composition, and review of proofs. Errors that could affect the content may be corrected during these processes.
Affiliation Information for All Authors: 1. Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104; 2. Department of Neuroscience, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104; 3. Department of Psychology, University of Pennsylvania, Philadelphia, PA 19104

Contributions:
Eric A Kaiser: Drafting/revision of the manuscript for content, including medical writing for content; Study concept or design; Analysis or interpretation of data
Harrison McAdams: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data; Study concept or design; Analysis or interpretation of data
Aleksandra Igdalova: Major role in the acquisition of data
Edda B Haggerty: Drafting/revision of the manuscript for content, including medical writing for content; Additional contributions: Drafted Figures
Brett L Cucchiara: Drafting/revision of the manuscript for content, including medical writing for content
David H Brainard: Drafting/revision of the manuscript for content, including medical writing for content; Study concept or design
Geoffrey K Aguirre: Drafting/revision of the manuscript for content, including medical writing for content; Study concept or design; Analysis or interpretation of data

Publication History: This manuscript was pre-published in BioRxiv doi: https://doi.org/10.1101/2020.12.12.422528

Number of characters in title: 131
Abstract Word count: 316
Word count of main text: 3717
References: 50
Figures: 4
Tables: 3

Statistical Analysis performed by: Harrison McAdams, PhD, University of Pennsylvania Geoffrey K Aguirre, MD, PhD; University of Pennsylvania

Search Terms: [ 101 ] Migraine

Study Funding: This work was supported by grants from the National Eye Institute (R01EY024681 to GKA and DHB; Core Grant for Vision Research P30 EY001583), National Institute of Neurological Disorders and Stroke (R25 NS065745), National Institute on Aging (5T32AG000255-13), and the Department of Defense (W81XWH-151-0447 to GKA).

Disclosures: E.A. Kaiser received royalties from patents in association with Alder Biopharmaceuticals related to anti-CGRP monoclonal antibodies for the treatment of migraine and photophobia, and received investigator-driven grant funding from Amgen, which manufactures an anti-CGRP monoclonal antibody for the treatment of migraine and not used for this study; H. McAdams reports no disclosures; A. Igdalova reports no disclosures; E.B. Haggerty reports no disclosures; B.L. Cucchiara reports no disclosures; D.H. Brainard has received grant funding and personal fees from Johnson and Johnson; G.K. Aguirre has received grant funding from Johnson and Johnson.
Abstract

*Objective:* To quantify interictal photophobia in migraine with and without aura using reflexive eye closure as an implicit measure of light sensitivity, and to assess the contribution of melanopsin and cone signals to these responses.

*Methods:* Participants were screened to meet criteria for one of three groups: headache-free (HAf) controls, migraine without aura (MwoA), and migraine with visual aura (MwA). MwoA and MwA participants were included if they endorsed ictal and interictal photophobia. Exclusion criteria included impaired vision, inability to collect usable pupillometry, and history of either head trauma or seizure. Participants viewed light pulses that selectively targeted melanopsin, the cones, or their combination during recording of orbicularis oculi electromyography (OO-EMG) and blinking activity.

*Results:* We studied twenty participants in each group. MwA and MwoA groups reported increased visual discomfort to light stimuli (Discomfort rating, 400% contrast, MwA: 4.84 [95% CI: 0.33, 9.35]; MwoA: 5.23 [0.96, 9.50]) as compared to HAf controls (2.71 [0, 6.47]). Time course analysis of OO-EMG and blinking activity demonstrated that reflexive eye closure was tightly coupled to the light pulses. The MwA group had greater OO-EMG and blinking activity in response to these stimuli (EMG activity, 400% contrast: 42.9%Δ [28.4, 57.4]; Blink activity, 400% contrast: 11.2% [8.8, 13.6]) as compared to the MwoA (EMG activity, 400% contrast: 9.9%Δ [5.8, 14.0]; Blink activity, 400% contrast: 4.7% [3.5, 5.9]) and HAf control (EMG activity, 400% contrast: 13.2%Δ [7.1, 19.3]; Blink activity, 400% contrast: 4.5% [3.1, 5.9]) groups.

*Conclusions:* Our findings suggest that the intrinsically-photosensitive retinal ganglion cells (ipRGCs), which integrate melanopsin and cone signals, provide the afferent input...
for light-induced reflexive eye closure in a photophobic state. Moreover, we find a
dissociation between implicit and explicit measures of interictal photophobia depending
on a history of visual aura in migraine. This implies distinct pathophysiology in forms of
migraine, interacting with separate neural pathways by which the amplification of ipRGC
signals elicit implicit and explicit signs of visual discomfort.
Introduction

People with migraine experience discomfort from light both during,¹-³ and between headaches (i.e., interictally).⁴-⁸ Discomfort from light is a feature of daily life for people with migraine,⁸-¹¹ and interictal photophobia is similar in people who have migraine with visual aura (MwA) and in those without aura (MwoA).⁴,⁵,⁹ It is possible that the similarity of light sensitivity symptoms in MwA and MwoA masks a difference in underlying physiology in these conditions.³

Photophobia is often measured by asking participants to report the light intensity threshold at which they begin to experience discomfort or pain. As an alternative to explicit self-report, an implicit sign of visual discomfort may be measured from the muscles of the eyelid.¹²,¹³ Reflexive blinking and squinting to bright light (i.e., “dazzle” or “photic blink”) is implemented by a sub-cortical (pre-tectal) reflex arc that does not require the visual cortex.¹⁴ There has been limited study of light-induced eyelid closure in people with migraine.¹³

In a recent study we had participants with migraine, and headache-free (HAf) controls, rate the discomfort produced by pulses of light.¹⁵ We found that explicit reports of discomfort were increased equally in MwA and MwoA as compared to controls, and that this effect was driven by both types of daylight-sensitive photoreceptors in the retina (i.e., the cones and melanopsin). Using the same subjects and stimuli, we now ask if this pattern of results is present for an implicit sign of light sensitivity, as measured by orbicularis oculi electromyography (OO-EMG) and video-oculography of blinking.
Methods

In a pre-registered study, we used silent substitution stimulation to selectively target melanopsin, the cones, or both. We presented 4-second pulses of these stimuli while we recorded OO-EMG and blinking in the contralateral eye via an infrared camera. The participants and stimuli presented here have been the subject of a prior paper on pupil responses and self-reported visual discomfort,\textsuperscript{15} the current data were collected in the same experimental sessions.

Standard Protocol Approvals, Registrations, and Patient Consents

The study was approved by the University of Pennsylvania Institutional Review Board. This study was the subject of an initial pre-registration document (https://osf.io/5ry67/) and subsequent addenda (project summary page: https://osf.io/qjxdf/). We have previously summarized our deviations from these protocols.\textsuperscript{15} There are three additional deviations pertaining to this study: 1) switching from root mean square to standard deviation to calculate EMG activity; 2) using a shorter (3400-msec) window for the quantification of responses; and 3) adding the quantification of the blink frames as a secondary measure. Written informed consent was obtained from all participants in this study.

Participants

A total of 60 participants (ages 25 to 40) were recruited from Philadelphia and the University of Pennsylvania. All recruited participants underwent screening using the Penn Online Evaluation of Migraine:\textsuperscript{16} an automated headache classification using the International Classification of Headache Disorders (ICHD)-3-beta criteria. The POEM also incorporates published questions regarding ictal and interictal photophobia that
were scored with a point for each “yes” response (referred as the Choi score). Recruited participants also completed the Visual Discomfort Score (VDS) survey; which was scored as described in our previous report. Candidate participants were required to meet all of the following inclusion criteria:

1) Migraine with visual aura (MwA): a) classification of migraine with visual aura by the POEM, b) Choi score of 6 or 7, c) a response of “yes” to the Choi query regarding the presence of photophobia during headache-free periods, d) one or more headaches within the prior month.

2) Migraine without aura (MwoA): a) classification of migraine without aura by the POEM, b) Choi score of 6 or 7, c) a response of “yes” to the Choi query regarding the presence of photophobia during headache-free periods, d) one or more headaches within the prior month.

3) Control: a) classification of mild non-migrainous headache or headache-free by the POEM, b) a response of “No” or “I don’t know” to a question regarding a family history of migraine, c) a response of “No” to a question regarding a history of childhood motion sickness, d) VDS score of 7 or lower.

Exclusion criteria related to impaired vision, inability to collect usable pupillometry, head trauma, and seizure history were as described previously. Participants were not excluded based on medication use and were allowed to continue to take their current medications during data collection.

**Stimuli**

We designed stimuli that target specific photoreceptor classes through silent substitution. In this approach, sets of light spectra are created that have the nominal
property of producing equal excitation of one or more “silenced” classes of photoreceptors, and varying excitation on one or more “targeted” photoreceptors. We targeted three main photoreceptor mechanisms: melanopsin, the cones, or their combination (referred to as “light flux”).

Stimuli were generated as described in prior reports. Briefly, we used a digital light synthesis engine (OneLight Spectra, Vancouver, BC, Canada) that produces stimulus spectra under digital control at 256 Hz. We created separate background and stimulation spectra that provided: 1) a nominal 400% unipolar Weber contrast on melanopsin while silencing the cones (melanopsin-directed background/stimulus pair), 2) 400% contrast on each L-, M-, and S-cone classes while silencing melanopsin (cone-directed background/stimulus pair), and 3) 400% contrast each on melanopsin and each L-, M-, and S-cone classes (light flux background/stimulus pair). Background spectra for each stimulus type differed in luminance but had similar chromaticity. We also produced contrast levels of 100% and 200% for each stimulus direction by scaling the relevant stimulus spectra. We did not explicitly silence rods or penumbral cones, although we believe that the properties of our stimuli minimize the contribution of these photoreceptors.

Stimuli were presented through a custom-made eyepiece with a circular, spatially uniform field of 27.5° diameter. The central 5° (diameter) of the field was obscured to minimize effects of macular pigment. Apparatus calibration and stimulus validation have been described.
**Experiment Structure**

Participants were studied during multiple sessions, usually held on different days. To reduce variation in circadian cycle across sessions, subsequent sessions for each participant were initiated within three hours of the time of day when that participant started their first session.

Acclimation to the testing room and apparatus, and pharmacologic dilation of the right eye, was as previously described. The participant remained in constant environmental light conditions during data collection. Participants viewed the stimuli through their pharmacologically dilated right eye and a 6 mm diameter artificial pupil to control retinal irradiance.

On each trial, the participant viewed a pulsed spectral modulation designed to target melanopsin, the cones, or both. The transition from the background to the stimulation spectrum (melanopsin, cones, or light flux), and the subsequent return to the background, were windowed with a 500-msec half-cosine. This minimized the entopic percept of a Purkinje tree in the melanopsin-directed stimulus. The duration of the pulse was 4 seconds, after which the stimulus field returned to the background spectrum (Figure 1b). EMG and infrared camera recordings continued for another twelve seconds after the pulse ended. Twelve seconds after the pulse ended, participants were prompted by an auditory cue to verbally rate their visual discomfort on a 0 to 10 scale. After each trial, there was a variable inter-trial-interval of 1.5 – 2.5 seconds (uniformly distributed) that reduced the predictability of the onset of the next trial.
Ten consecutive trials that targeted the same photoreceptor direction but varied in contrast were grouped together during an acquisition. The ordering of the contrast levels (100, 200, 400%) was counterbalanced, and the first trial was discarded so that all retained trials had controlled first-order stimulus history. A total of 6 acquisitions, 2 of each photoreceptor direction, comprised a single session. Acquisitions were ordered such that consecutive acquisitions were not of the same photoreceptor direction. We attempted to gather 4 sessions of data for each participant but retained all participants who completed two sessions that contained at least six acceptable trials—as judged by pupillometry—for each stimulus type (photoreceptor direction and contrast level). Participants did not complete all four sessions for a variety of reasons.

Electromyography

We recorded OO-EMG starting prior to pulse onset and ending 12 seconds after pulse offset (Figure 1b,c). This measure is sensitive to tonic (squinting) and phasic (blinking) eye closure. There was a 1.1-sec delay between the start of the trial and the initiation of EMG recording due to a slow computational operation; thus, the period of EMG recording prior to pulse onset was approximately 400 msecs. Prior to electrode placement, the skin surface was wiped with an alcohol pad. Two small reference electrode pads were placed inferior to each eye, and a ground lead was placed on the neck. EMG was recorded with the BioNomadix 2-Channel EMG equipment (Biopac Systems, Inc). Participants were informed that the EMG electrodes measure an “eye response”. This wording was designed to avoid cueing the participant to the use of the EMG as an index of discomfort; we did not assess what assumptions participants had about our measurement.
Blink quantification via infrared videography

We recorded blinks from the left eye of the participant (contralateral to the eye receiving stimuli) using an infrared (IR) camera (Pupil Labs GmbH) mounted on a post ~25 mm from the eye. The camera has two IR LEDs mounted adjacent to the lens, providing illumination of the eye. A 60-Hz video clip was recorded for each trial, starting 1.5-s prior to pulse onset and ending 12-s after pulse offset (Figure 1e,f). These videos were processed using custom software (https://github.com/gkaguirrelab/transparentTrack). Blinking was quantified as the number of video frames in which the glints (first Purkinje images) from the active IR light sources were absent.

Analysis

Data analysis was performed using custom MATLAB code (Mathworks). EMG activity was quantified by calculating the standard deviation of the recorded voltage within a sliding 500-msec window. The activity time series were normalized as percentage change relative to activity occurring prior to pulse onset.

First, we examined the time-course of EMG responses for each group of participants, averaged across the three stimulus types (cone, melanopsin, and light-flux). The mean OO-EMG response across trials and stimuli at each contrast level was calculated, and then averaged across participants within each group.

Second, we examined the time-course of blink activity for each group of participants, averaged across the three stimulus types (cone, melanopsin, and light-flux). Blink activity was defined as a binary vector (i.e., blink or no blink). Then across trials for a subject, the average of such vectors was calculated, and a sliding window
was applied to yield the percentage of trials in which a blink occurred. The mean percent trials with blinks at each contrast level were calculated, and then averaged across participants within each group.

We quantified the effect of our stimuli upon the OO-EMG and blink measures by calculating the average response over a 3400-msec window starting 300 msecs after pulse onset and ending 300 msecs prior to pulse offset. This window was selected to avoid the influence of blinking at stimulus onset or offset in the measured response. For both OO-EMG activity and percent of blink frames, we took the mean response across trials within a participant, and the mean across participants within a group.

Data availability and analysis code

Analysis results using the pre-registered parameters, analysis code, and data are available online (https://github.com/gkaguirrelab/melSquintAnalysis).

Results

Participant characteristics

We studied 20 individuals in each of three groups: migraine with aura (MwA), migraine without aura (MwoA), and headache-free (HAf) controls. The groups were well matched for age (Table 1). The non-photophobic HAf group contained fewer female participants than the photophobic migraine groups, reflecting the higher female to male ratio observed in migraine. Participants in both migraine groups reported similar headache disability and frequency (~4 headache days per month) from migraine, indicating that both migraine groups contained individuals with episodic migraine and moderate disability. Medication use among the two migraine groups was similar,
although more MwA participants reported aspirin / acetaminophen / caffeine (Excedrin™) and triptan use.

*Both MwA and MwoA subjects report enhanced, explicit discomfort to light*

Subjects were asked to verbally rate, on a scale of 0 to 10, the visual discomfort produced by each presented stimulus. In a previous presentation of these data, we found that stimulation of either the cones or melanopsin evoked a report of visual discomfort. Here, we collapsed the data across photoreceptor target and examined the effect of stimulus contrast and headache diagnosis. Figure 2 presents the mean reported discomfort level for each group as a function of the contrast of the stimulus. For all three groups, increased stimulus contrast evoked reports of greater discomfort. For both of the migraine populations, discomfort levels were increased overall. This was especially evident at the 400% contrast level (MwA: 4.84 ± 2.30; MwoA: 5.23 ± 2.18; HAf controls: 2.71 ± 1.92). Our previous analysis of these data showed that this effect of migraine was present for both cone and melanopsin stimulation.

*Only MwA subjects demonstrate enhanced OO-EMG responses to light*

We examined the effect of the light stimulus pulse upon OO-EMG activity as a function of time and stimulus contrast across the 16-second recording interval (collapsed across photoreceptor target) for each of the studied groups. For the 100% contrast stimuli, the temporal evolution of EMG activity is indistinguishable between the studied groups (Figure 3a, left). There is a small increase in the EMG signal during the stimulus presentation, followed by an additional, transient increase at stimulus offset. Based on inspection of video recording of the eye contralateral to the stimulus, we
interpret the offset response as participants suppressing blinks during the stimulus, and then engaging in increased blinking following stimulus offset. The response to the 200% contrast stimulus is similar (Figure 3a, center), except for an increased EMG response during the light pulse in only the MwA group. This effect becomes pronounced in response to the maximal, 400% contrast pulse, for which only the MwA group demonstrates a large change in EMG activity during the stimulus (Figure 3a, right).

We quantified the change in OO-EMG activity during the stimulus pulse for each group and contrast level (Figure 3b). We compared OO-EMG activity from the pre-stimulus baseline to activity during the middle 3400 msec of the stimulus pulse. In MwA participants, light pulses elicited elevated OO-EMG activity with increasing levels of contrast. This was particularly evident in response to 400% contrast, which evoked an increase in mean (±SEM) EMG activity of 42.9 ± 7.4%. Light pulses evoked smaller elevations in OO-EMG activity compared to baseline in controls or MwoA participants at 400% contrast (mean responses: HAf controls: 13.2 ± 3.1%, MwoA: 9.9 ± 2.1%).

We examined the separate effect of stimuli that targeted the cones and melanopsin upon the OO-EMG response. Overall, we found that signals from both of these photoreceptor classes produced larger OO-EMG response in the MwA group as compared to the MwoA and HAf groups. Table 2 provides the mean OO-EMG response across subjects as a function of group, contrast level, and photoreceptor target.

*Only MwA subjects demonstrate enhanced blinking in response to light*

People engage in both blinking and squinting in response to a bright light. The OO-EMG signal reflects both types of muscle activity. We sought to confirm our OO-
EMG findings by examining a second measure of reflexive eyelid closure. Analyzing infrared video frames of the contralateral eye, we obtained an estimate of the percent of time subjects spent blinking in the period following pulses of light.

Like the OO-EMG activity, we examined the effect of the light stimulus pulse upon blinking as a function of time and stimulus contrast across the 16-second recording interval. For the 100% contrast stimuli, the temporal evolution of blinking is similar between the studied groups (Figure 4a, left). Subjects attempt to keep their eye open during the stimulus, and then engage in increased blinking following the offset of the light pulse. At 200% contrast (Figure 4a, center), a slight increase in blinking during the spectral pulse is seen in the MwA group as compared to the MwoA and HAf control groups. This effect becomes prominent in the 400% contrast data, in which an increase in blinking with stimulus onset can be seen for the MwA group (Figure 4a, right).

We quantified the percent of time spent blinking during the middle 3400 msecs of the stimulus pulses for each group and contrast level (Figure 4b). In MwA participants, spectral pulses increased the percent of blink frames with increasing levels of contrast, particularly at 400% contrast (mean ± SEM blink frames: 11.2 ± 1.2%). Lower rates of blinking were seen in the MwoA (4.7 ± 0.6%) and HAf controls (4.5 ± 0.7%). These findings parallel our measurements of OO-EMG activity.

We examined the separate effect of stimuli that targeted the cones and melanopsin upon the blink response. Again, we found that stimulation of either of these photoreceptor classes produced a larger blink response in the MwA group as compared to the MwoA or HAf groups (Table 3).
Discussion:

We find a clear dissociation between explicit and implicit measures of visual discomfort in participants who have migraine with interictal light sensitivity. While migraine headache generally is associated with a verbal report of increased discomfort from pulses of light, only those participants with migraine with visual aura had changes in implicit, reflexive measures of visual discomfort (blinking and squinting). Our study adds to a relatively limited set of findings of measurable differences in migraine between people with and without aura. Similar to our prior study with these stimuli, we find that both cone and melanopsin stimulation elicit reflexive eye closure. This finding implicates the intrinsically photosensitive retinal ganglion cells (ipRGCs), which both contain melanopsin and receive extrinsic input from the cones.

The two migraine study populations were well matched in demographic properties and headache frequency and disability, in their reports of visual disability in daily life, and in measures of circadian and seasonal sensitivity (Table 1). The MwA and MwoA groups also reported nearly identical levels of visual discomfort in response to the light pulse stimuli (Figure 2). Despite these manifest similarities, the two groups had markedly different responses in measures of reflexive eyelid closure (Figures 3b, 4b). It is possible that there are further, individual differences related to aura or headache frequency. In post-hoc tests within the MwA group, we did not find a significant relationship between headache recency and either EMG (Spearman’s rho = -0.29, p = 0.12) or blinking response (rho = -0.07, p=0.72). A larger study focused upon individual differences may reveal that reflexive eyelid closure is a “post-drome” phenomenon, similar to observations of altered pupillary responses following a migraine event or an effect of more frequent aura as greater light sensitivity has been observed in
chronic compared to episodic migraine. Interestingly the stimuli in our protocol induced aura in the midst of an experimental session in one instance, and we are aware of at least 8 instances of participants experiencing migraine within 6 hours following an experimental session.

Whether migraine with and without aura reflect distinct entities has been the subject of some debate. Despite clinical and demographic differences, genetic differences, for example, have proven elusive. There are several reports of altered neural or vascular physiology specific to MwA. A consistent finding has been a reduction in neural habituation in MwA, although similar findings have also been observed in MwoA.

We find here a difference between migraine with and without aura in reflexive eyelid closure in response to light. The photic blink reflex relies upon brainstem mechanisms, which are intimately related with pathways for the acoustic and tactile (i.e., trigeminal) blink reflex. A decrease in habituation of the trigeminally-mediated blink reflex has been shown in migraine generally, and a recent study found that people with migraine respond with a threshold amount of OO-EMG activity at lower levels of light compared to healthy controls (although that study did not distinguish between migraine participants with and without visual aura).

Trigeminal and retinal signals appear to interact and potentiate each other. In migraine, noxious trigeminal stimulation decreases visual discomfort thresholds, increases light-induced pain, and potentiates visual cortex activity in response to light. The reverse association is also found, as light decreases pain thresholds for trigeminal stimulation. Trigeminal sensitization also appears to facilitate photophobia in blepharospasm, which is a dystonia of repetitive eye closure. In an fMRI study of a
patient with transient photophobia from corneal irritation, visual stimulation was found to activate the trigeminal ganglion and trigeminal nucleus caudalis, in agreement with similar measurements in rodents. The ability of corneal irritation to induce light aversion is attenuated in mice lacking ipRGCs, suggesting a link between ipRGC signals and trigeminal nociception. Furthermore, the somatic discomfort from bright light may in part derive from the convergence of ipRGC and dura-sensitive trigeminal afferents upon the posterior thalamus.

An intriguing possibility is that melanopsin expression in trigeminally-innervated tissue could itself contribute to visual discomfort. Melanopsin has been found in the trigeminal ganglia of mice and humans, and the cornea and iris of mice. In rodents with optic nerve lesions, bright light has been reported to nonetheless potentiate the trigeminal blink reflex, and induce light aversion in a migraine-like state. In our study, however, extra-retinal melanopsin signaling seems unlikely to have played a substantial role, as the stimulus was transmitted through an artificial pupil into the pharmacologically dilated eye, minimizing the area of stimulated cornea and iris.

Given the dissociation of explicit and implicit discomfort measures in the presence and absence of visual aura, it seems likely that the physiologic mechanism of enhanced reflexive eye closure differs at some point from that of an enhanced conscious report of visual discomfort. Evidence from animal studies, and from our recent and current measures in humans, suggest that the ipRGCs are a source of signals for light aversion. There are several classes of these melanopsin-containing cells, and they have diverse and widespread projections both to cortical pathways (including the visual and somatosensory thalamic nuclei) and to sub-cortical, brainstem
sites. While we suspect that there exists a brainstem site that receives converging trigeminal and ipRGC input, and which mediates reflexive eye closure, we are unaware of the demonstration of a neuroanatomic site with these properties. We interpret our current findings as suggesting that people with MwA and MwoA have an amplification of ipRGC-based signals for the conscious report of visual discomfort (perhaps via a cortical route), but that only in MwA is there an alteration of brainstem mechanisms for light-induced, reflexive eyelid closure.
**Study Funding:**

This work was supported by grants from the National Eye Institute (R01EY024681 to GKA and DHB; Core Grant for Vision Research P30 EY001583), National Institute of Neurological Disorders and Stroke (R25 NS065745), National Institute on Aging (5T32AG000255-13), and the Department of Defense (W81XWH-151-0447 to GKA).

**Disclosures:**

E.A. Kaiser received royalties from patents in association with Alder Biopharmaceuticals related to anti-CGRP monoclonal antibodies for the treatment of migraine and photophobia, and received investigator-driven grant funding from Amgen, which manufactures an anti-CGRP monoclonal antibody for the treatment of migraine and not used for this study; H. McAdams reports no disclosures; A. Igdalova reports no disclosures; E.B. Haggerty reports no disclosures; B.L. Cucchiara reports no disclosures; D.H. Brainard has received grant funding and personal fees from Johnson and Johnson; G.K. Aguirre has received grant funding from Johnson and Johnson.

**Authors:**

<table>
<thead>
<tr>
<th>Name</th>
<th>Location</th>
<th>Contribution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eric A. Kaiser</td>
<td>University of Pennsylvania, Philadelphia</td>
<td>Designed and conceptualized study; interpreted the data, drafted and revised the manuscript for intellectual content</td>
</tr>
<tr>
<td>Harrison McAdams</td>
<td>University of Pennsylvania, Philadelphia</td>
<td>Designed and conceptualized study; major role in acquisition of data; analyzed and interpreted the data; revised the manuscript for intellectual content</td>
</tr>
<tr>
<td>Aleksandra Igdalova</td>
<td>University of Pennsylvania, Philadelphia</td>
<td>Major role in acquisition of data</td>
</tr>
</tbody>
</table>

Copyright © 2021 American Academy of Neurology. Unauthorized reproduction of this article is prohibited
<table>
<thead>
<tr>
<th>Name</th>
<th>University of Pennsylvania, Philadelphia</th>
<th>Philadelphia data</th>
</tr>
</thead>
<tbody>
<tr>
<td>Edda B Haggerty¹</td>
<td>Drafted figures and revised the manuscript for intellectual content</td>
<td></td>
</tr>
<tr>
<td>Brett Cucchiara¹</td>
<td>Designed and conceptualized study; revised the manuscript for intellectual content</td>
<td></td>
</tr>
<tr>
<td>David H Brainard²</td>
<td>Designed and conceptualized study; revised the manuscript for intellectual content</td>
<td></td>
</tr>
<tr>
<td>Geoffrey K Aguirre</td>
<td>Designed and conceptualized study; interpreted the data; drafted and revised the manuscript for intellectual content</td>
<td></td>
</tr>
</tbody>
</table>
References:

29. Ligthart L, Boomsma DI, Martin NG, Stubbe JH, Nyholt DR. Migraine with aura and migraine without aura are not distinct entities: further evidence from a large Dutch population study. Twin Res Hum Genet 2006;9:54-63.
Figure Legends:

Figure 1. Experimental Overview. a. The light from a digital spectral integrator was presented to the pharmacologically dilated right eye of the participant through an artificial pupil. Blinking of the left eye was recorded with an infrared (IR) camera. b. Each trial featured a four-second spectral pulse. EMG and IR camera recordings started prior to the onset of the pulse and continued for 16 sec. Then participants were prompted to verbally rate their visual discomfort on a 0 to 10. There was an inter-trial interval that varied between 1.5 and 2.5 s. c. To record orbicular oculi electromyography (OO-EMG), electrodes were placed inferior to both eyes. OO-EMG activity was calculated from the percent change in the standard deviation of the voltage from baseline over a 3400 msec window starting 300 msec after pulse onset and ending 300 msec before pulse offset.
Figure 2. Discomfort rating in response to spectral pulses. The average verbal discomfort rating on a scale of 0 to 10 within each group (n = 20 participants per group) is shown at each contrast level. The stimuli were presented at three different contrast levels (100, 200, and 400%), and these (log-spaced) values define the x-axis. The discomfort ratings for the three stimulus types were averaged across stimulus types within each group and shown as a filled circle. Error bars represent ±SEM. The best-fit line to the mean discomfort rating across participants as a function of log contrast is shown as a solid line for each group.
Figure 3. OO-EMG activity in response to spectral pulses. 

a. Time course of OO-EMG activity. The average OO-EMG across participants within each group (n = 20 participants per group) is shown at each contrast level (columns: 100, 200, and 400%). For each contrast level, responses from the three groups are superimposed and shown as a function of time over the 16 second recording interval. The 4-sec stimulus pulse is indicated by a black bar, and the middle 3400 msecs of this period is highlighted in yellow. The shaded area is the ±SEM across participants within a group. OO-EMG is expressed as percentage change [\%\Delta] relative to activity occurring prior to pulse onset.

b. The across-subject, average OO-EMG activity during the middle 3400 msecs of the stimulus pulse is shown for each group (n = 20 participants per group) at each contrast level. The stimuli were presented at three different contrast levels (100, 200, and 400%), and these (log-spaced) values define the x-axis. Error bars represent ±SEM across subjects.
Figure 4. Blink activity in response to spectral pulses. a. Time course of blinking activity. The average blink activity across participants within each group (n = 20 participants per group) is shown at each contrast level (columns: 100, 200, and 400%). For each contrast level, responses from the three groups are superimposed and shown as a function of time over the 16 second recording interval. The 4-sec stimulus pulse is indicated by a black bar, and the middle 3400 msecs of this period is highlighted in yellow. The shaded area is the ±SEM across participants within a group. Blink activity was quantified as the percentage of video frames classified as blinks. b. The across-subject, average blink activity during the middle 3400 msecs of the stimulus pulse is shown for each group (n = 20 participants per group) at each contrast level. The stimuli were presented at three different contrast levels (100, 200, and 400%), and these (log-spaced) values define the x-axis. Error bars represents ±SEM across subjects.
<table>
<thead>
<tr>
<th>Group</th>
<th>No. of women</th>
<th>Age (years)</th>
<th>Headache days /3 months</th>
<th>Disability MIDAS</th>
<th>HIT-6</th>
</tr>
</thead>
<tbody>
<tr>
<td>Controls</td>
<td>13/20</td>
<td>31 (5)</td>
<td>1.3 (1.4)</td>
<td>0.5 (0.8)</td>
<td>40.7 (4.1)</td>
</tr>
<tr>
<td>MwoA</td>
<td>17/20</td>
<td>30 (4)</td>
<td>11.7 (9.7)</td>
<td>16.0 (13.7)</td>
<td>60.0 (8.8)</td>
</tr>
<tr>
<td>MwA</td>
<td>19/20</td>
<td>31 (4)</td>
<td>13.1 (8.9)</td>
<td>18.6 (15.3)</td>
<td>60.6 (8.0)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Group</th>
<th>NSAID</th>
<th>APAP</th>
<th>Excedrin™</th>
<th>Triptan</th>
<th>Preventive</th>
</tr>
</thead>
<tbody>
<tr>
<td>Controls</td>
<td>14</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>MwoA</td>
<td>17</td>
<td>2</td>
<td>1</td>
<td>1</td>
<td>3</td>
</tr>
<tr>
<td>MwA</td>
<td>16</td>
<td>5</td>
<td>6</td>
<td>5</td>
<td>1</td>
</tr>
</tbody>
</table>

Table 1. Subject demographic and clinical characteristics. Participants were asked to report the number of headache days they had experienced over the prior three months. The Migraine Disability Assessment Test (MIDAS) and the Headache Impact Test (HIT-6) measure headache disability. Where appropriate, the mean value (and standard deviation) across subjects is reported. Medication use is summarized within five categories: NSAID – non-steroidal anti-inflammatory for any indication; APAP – acetaminophen for any indication; Excedrin™ – use of any one of multiple formulations that combine acetaminophen with caffeine, aspirin, diphenhydramine, and/or phenylephrine; triptan – any 5HT$_{1B/D}$ receptor agonist; preventive – any one of several classes of medications used to decrease headache.
<table>
<thead>
<tr>
<th>Stimulus</th>
<th>Group</th>
<th>Mean ± SEM</th>
<th>Mean ± SEM</th>
<th>Mean ± SEM</th>
</tr>
</thead>
<tbody>
<tr>
<td>Light Flux</td>
<td>HAf</td>
<td>5.4 ± 1.8</td>
<td>7.6 ± 2.7</td>
<td>17.7 ± 7.8</td>
</tr>
<tr>
<td></td>
<td>MwoA</td>
<td>5.7 ± 1.8</td>
<td>7.2 ± 2.8</td>
<td>11.7 ± 4.3</td>
</tr>
<tr>
<td></td>
<td>MwA</td>
<td>10.9 ± 3.1</td>
<td>20.9 ± 6.0</td>
<td>46.2 ± 12.6</td>
</tr>
<tr>
<td>Melanopsin</td>
<td>HAf</td>
<td>8.9 ± 3.1</td>
<td>7.3 ± 2.4</td>
<td>13.5 ± 4.0</td>
</tr>
<tr>
<td></td>
<td>MwoA</td>
<td>6.8 ± 2.1</td>
<td>8.7 ± 2.3</td>
<td>11.4 ± 3.7</td>
</tr>
<tr>
<td></td>
<td>MwA</td>
<td>12.0 ± 2.8</td>
<td>14.1 ± 3.3</td>
<td>45.1 ± 15.3</td>
</tr>
<tr>
<td>Cones</td>
<td>HAf</td>
<td>4.0 ± 1.6</td>
<td>3.4 ± 1.7</td>
<td>8.5 ± 2.9</td>
</tr>
<tr>
<td></td>
<td>MwoA</td>
<td>7.0 ± 2.2</td>
<td>4.1 ± 1.4</td>
<td>6.5 ± 2.9</td>
</tr>
<tr>
<td></td>
<td>MwA</td>
<td>11.2 ± 2.4</td>
<td>15.2 ± 4.1</td>
<td>37.2 ± 10.6</td>
</tr>
<tr>
<td>Combined</td>
<td>HAf</td>
<td>6.1 ± 1.3</td>
<td>6.1 ± 1.3</td>
<td>13.2 ± 3.1</td>
</tr>
<tr>
<td></td>
<td>MwoA</td>
<td>6.5 ± 1.1</td>
<td>6.7 ± 1.3</td>
<td>9.9 ± 2.1</td>
</tr>
<tr>
<td></td>
<td>MwA</td>
<td>11.4 ± 1.6</td>
<td>16.7 ± 2.6</td>
<td>42.9 ± 7.4</td>
</tr>
</tbody>
</table>

Table 2. OO-EMG activity in response to light pulses. The average OO-EMG activity within each group (n = 20 participants per group) is shown at each contrast level for each stimulus type (light flux, melanopsin, cones) at each contrast level. The OO-EMG “combined” responses represent average of all the three stimulus types within each group. The stimuli were presented at three different contrast levels (100, 200, and 400%). OO-EMG activity is expressed as percentage change [%Δ] relative to the standard deviation measure prior to pulse onset.
Table 3. Blink activity in response to spectral pulses. The average blink activity within each group (n = 20 participants per group) is shown for each stimulus type (light flux, melanopsin, cones) at each contrast level. The “combined” blink responses represent average of all the three stimulus types within each group. The stimuli were presented at three different contrast levels (100, 200, and 400%). Blink activity is expressed as the percent of blink frames over a 3400-msec window.

<table>
<thead>
<tr>
<th>Stimulus</th>
<th>Group</th>
<th>Contrast 100%</th>
<th>Mean ± SEM</th>
<th>Contrast 200%</th>
<th>Mean ± SEM</th>
<th>Contrast 400%</th>
<th>Mean ± SEM</th>
</tr>
</thead>
<tbody>
<tr>
<td>Light Flux</td>
<td>HAf</td>
<td>4.7 ± 1.2</td>
<td>4.4 ± 1.3</td>
<td>4.2 ± 1.3</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>MwoA</td>
<td>4.7 ± 1.0</td>
<td>4.8 ± 1.1</td>
<td>5.7 ± 1.3</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>MwA</td>
<td>7.2 ± 1.6</td>
<td>8.8 ± 1.8</td>
<td>12.4 ± 2.5</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Melanopsin</td>
<td>HAf</td>
<td>5.4 ± 1.3</td>
<td>4.8 ± 1.1</td>
<td>4.9 ± 1.2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>MwoA</td>
<td>3.8 ± 0.8</td>
<td>3.8 ± 0.9</td>
<td>3.9 ± 0.9</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>MwA</td>
<td>7.0 ± 1.6</td>
<td>7.8 ± 1.6</td>
<td>10.9 ± 1.9</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cones</td>
<td>HAf</td>
<td>4.8 ± 1.2</td>
<td>4.4 ± 1.3</td>
<td>4.5 ± 1.1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>MwoA</td>
<td>4.2 ± 0.0</td>
<td>4.2 ± 0.9</td>
<td>4.5 ± 1.1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>MwA</td>
<td>6.8 ± 1.7</td>
<td>8.3 ± 1.8</td>
<td>10.2 ± 2.1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Combined</td>
<td>HAf</td>
<td>4.9 ± 0.7</td>
<td>4.5 ± 0.7</td>
<td>4.5 ± 0.7</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>MwoA</td>
<td>4.2 ± 0.5</td>
<td>4.3 ± 0.6</td>
<td>4.7 ± 0.6</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>MwA</td>
<td>7.0 ± 0.9</td>
<td>8.3 ± 1.0</td>
<td>11.2 ± 1.2</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>